Association of the endothelial nitric oxide synthase gene G894T polymorphism with the risk of diabetic nephropathy in Qassim region, Saudi Arabia-A pilot study

Meta Gene

Volumn 2, Issue 1, 2014, Pages 392-402

  Mackawy, Amal Mohammed Husein ^a   Khan, Amjad Ali ^b   Badawy, Mohammed El Sayed ^c  

^a ZAGAZIG UNIVERSITY   (Egypt)

^b QASSIM UNIVERSITY   (Saudi Arabia)

^c King Fahd Specialist Hospital   (Saudi Arabia)

Author keywords

Diabetic nephropathy; E NOS gene G894T polymorphism; Endothelial nitric oxide synthase (e NOS) enzyme; Microangiopathy in type 2 diabetes mellitus (DM)

Indexed keywords

CHOLESTEROL; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GLUCOSE; HEMOGLOBIN A; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; NITRIC OXIDE; TRIACYLGLYCEROL; GENOMIC DNA; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NITRATE;

ADULT; ALLELE; ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DNA POLYMORPHISM; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK FACTOR; SAUDI ARABIA; BLOOD SAMPLING; CASE CONTROL STUDY; CLINICAL EXAMINATION; CREATININE BLOOD LEVEL; DNA DETERMINATION; DNA EXTRACTION; ENDOTHELIAL NITRIC OXIDE SYNTHASE GENE; GENE; GENE SEQUENCE; GENETIC POLYMORPHISM; GLUCOSE BLOOD LEVEL; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PILOT STUDY; PROTEIN ANALYSIS; QUESTIONNAIRE; RISK; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL ANALYSIS;

EID: 84901804437     PISSN: None     EISSN: 22145400     Source Type: Journal    
DOI: 10.1016/j.mgene.2014.04.009     Document Type: Article

References (53)

1. Abraham, E.C.K., Huff, T.A., Cope, N.E., et al., 1978. De-termination of glycosylated hemoglobins with a new micro-column procedure. Diabetes 27, 931-937.
2. Ahluwalia, T.S., Ahuja, M., Rai, T.S., Kohli, H.S., Sud, K., Bhansali, A., Khullar, M., 2008. Endothelial nitric oxide synthase gene haplotypes and DN among Asian Indians. Mol. Cell. Biochem. 314 (1-2), 9-17.
3. Anon, 2008. Stakeholder opinions: type 2 diabetes in the UAE and Saudi Arabia growth opportunities in fragmented markets. Datamonitor ((115 pp.), published Dec).
4. Assmann, G., Schriewer, H., Schmitz, G., Hagele, E.O., 1983. Quantification of high-density-lipoprotein cholesterol by precipitation with phosphotungstic acid/MgCl2. Clin. Chem. 29, 2026-2030.
5. Badawy, A., Elbaz, R., Abbas, A.M., Elgendy, A., Kizilbash, N.A., Eldesoky, A., Wafa, A., 2011. Oxidative stress and not endothelial nitric oxide synthase gene polymorphism involved in diabetic nephropathy. J. Diabetes Endocrinol. 2 (3), 29-35.
6. Bank, N., Aynedjian, H.S., 1993. Role of EDRF (nitric oxide) in diabetic renal hyperfiltration. Kidney Int. 43, 1306-1312.
7. Brownlee, M., 2005. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 54, 1615-1625.
8. Bucolo, G., David, H., 1973. Quantitative determination of plasma triglycerides by the use of enzymes. Clin. Chem. 19, 476-482.
9. Busik, J.V., Mohr, S., Grant, M.D., 2008. Hyperglycemia-induced reactive oxygen species toxicity to endothelial cells is dependent on paracrine mediators. Diabetes 57, 1952-1965.
10. Casas, J.P., Cavalleri, G.L., Bautista, L.E., Smeeth, L., Humphries, S.E., Hingorani, A.D., 2006. Endothelial nitric oxide synthase gene polymorphisms and cardiovascular disease: a HuGE review. Am. J. Epidemiol. 164, 921-935.
11. Chiarelli, F., Gaspari, S., Marcovecchio, M.L., 2009. Role of growth factors in diabetic kidney disease. Horm. Metab. Res. 41 (8), 585-593.
12. Drexler, H., Horning, B., 2009. Endothelial dysfunction in human disease. J. Mol. Cell. Cardiol. 31 (1), 51-60.
13. Evans, J.L., Goldfine, I.D., Maddux, B.A., 2002. Oxidative stress and stress activated signaling pathways: a unifying hypothesis of type 2 diabetes. Endocr. Rev. 23, 599-22.
14. Ezzidi, I., Mtiraoui, N., Mahjoub, T., 2008. Association of endothelial nitric oxide synthase Glu298Asp, 4b/a, and -786 T N C gene variants with diabetic nephropathy. Diabetes Complicat. 22 (5), 331-338.
15. Fairchild, T.A., Fulton, D., Fontana, J.T., et al., 2001. Acidic hydrolysis as a mechanism for the cleavage of the Glu298Asp variant of human endothelial nitric oxide synthase. J. Biol. Chem. 276, 26674-26679.
16. Forbes, J.M., Coughlan, M.T., Cooper, M.E., 2008. Oxidative stress as a major culprit in kidney disease in diabetes. Diabetes 57, 1446-1454.
17. Green, L.C., Wagner, D.A., Glogowski, J., 1982. Analysis of nitrate, nitrite and N nitrite in biological fluids. Anal. Biochem. 126, 131-138.
18. Gross, J.L., de Azevedo, M.J., Silveiro, S.P., et al., 2008. Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes Care 2, 164-176.
19. Gryglewski, R.J., Palmer, R.M., Moncada, S., 1986. Superoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor. Nature 320, 454-456.
20. He, Y., Fan, Z., Zhang, J., et al., 2011. Polymorphisms of eNOS gene are associated with diabetic nephropathy: a meta-analysis. Mutagenesis 26, 339-349.
21. Jeerooburkhan, N., Jones, L.C., Bujac, S., 2001. Genetic and environmental determinants of serum nitrogen oxides and risk of ischemic heart disease. Hypertension 38 (5), 1054-1061.
22. Lamb, E.J., MacKenzie, F., Stevens, P.E., 2009. How should proteinuria be detected and measured? Ann. Clin. Biochem. 46, 205-217.
23. Manjula, B., 2011. Endothelial nitric oxide synthase (eNOS) variants in cardiovascular disease: pharmacogenomic implications. Indian J. Med. Res. 133 (5), 464-466.
24. Manolio, T.A., Brooks, L.D., Collins, F.S., 2008. A HapMap harvest of insights into the genetics of common disease. J. Clin. Invest. 118, 1590-1605.
25. McLennan, S.V., Fisher, E., Martell, S.Y., et al., 2000. Effects of glucose on matrix metalloproteinase and plasmin activities in mesangial cells: possible role in diabetic nephropathy. Kidney Int. 58 (77), 81-87.
26. Mohsen, K., Faouzi, A., Maryline, C., et al., 2006. Hyperhomocysteinemia, endothelial nitric oxide synthase polymorphism, and risk of coronary artery disease. Clin. Chem. 1 (52), 53-58.
27. Mollsten, A., Lajer, M., Jorsal, A., 2009. The endothelial nitric oxide synthase gene and risk of diabetic nephropathy and development of cardiovascular disease in type 1 diabetes. Mol. Genet. Metab. 97 (1), 80-84.
28. Moon, J., Yoon, S., Kim, E., et al., 2002. Lack of evidence for contribution of Glu298Asp (894G N T) polymorphism of endothelial nitric oxide synthase gene to plasma nitric oxide levels. Thromb. Res. 107, 129-134.
29. Murray, R.L., Kaplan, A., 1989. Creatinine. Clinical ChemistryThe C.V. Mosby Co. St. Louis, Toronto. Princeton pp. 1261-1266 (and 418).
30. Nishevitha, N.S., Angeline, T., Nirmala, J., 2009. Endothelial nitric oxide synthase (eNOS) Glu à Asp polymorphism (G894T) among south Indians. Indian J. Med. Res. 129, 68-71.
31. Noiri, E., Satoh, H., Taguchi, J., 2002. Association of eNOS Glu298Asp polymorphism with end-stage renal disease. Hypertension 40, 535-540.
32. Ohishi, K., Carmines, P.K., 1995. Superoxide dismutase restores the influence of nitric oxide on renal arterioles in diabetes mellitus. J. Am. Soc. Nephrol. 5, 1559-1566.
33. Orsonneau, Jl, Douet, P., Massoubre, C., Lustenberger, P., Bernard, S., 1989. An improved pyrogallol red-molybdate method for determining total urinary protein. Clin. Chem. 35 (11), 2233-2236.
34. Rabbani, S., Moin, U., Shiva, P., Farha, D., Kaiser, J., 2011. Evidence of association of a common variant of the endothelial nitric oxide synthase gene (Glu298 Asp polymorphism) to coronary artery disease in South Indian population. J. Med. Genet. Genomics 3 (1), 13-18.
35. Ritt, M., Ott, C., Delles, C., et al., 2008. Impact of the endothelial nitric oxide synthase gene 894G N T polymorphism on renal endothelial function in patients with type 2 diabetes. Pharmacogenet. Genomics 18, 699-707.
36. Rossi, G.P., Taddei, S., Virdis, A., Cavallin, M., Ghiadoni, L., Favilla, S., Versari, D., Sudano, I., Pessina, A.C., Salvetti, A., 2003. The T-786C and Glu298Asp polymorphisms of the endothelial nitric oxide gene affect the forearm blood flow responses of Caucasian hypertensive patients. J. Am. Coll. Cardiol. 41938-41945.
37. Salimi, S., Firoozrai, M., Zand, H., Nakhaee, A., Shafiee, S.M., Tavilani, H., Mohebbi, A., 2010. Endothelial nitric oxide synthase gene Glu298Asp polymorphism in patients with coronary artery disease. Ann. Saudi Med. 30 (1), 33-37. http://dx.doi.org/10.4103/ 0256-4947.59370.
38. Schachinger, V., Britten, M.B., Zeiher, A.M., 2000. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 101, 1899-1906.
39. Schnackenberg, C.G., Wilcox, C.S., 2001. The SOD mimetic tempol restores vasodilation in afferent arterioles of experimental diabetes. Kidney Int. 59, 1859-1864.
40. Shin, S.Y., Baek, S.H., Chang, K.Y., et al., 2004. Relations between eNOS Glu298Asp polymorphism and progression of DN. Diabetes Res. Clin. Pract. 65, 257-265.
41. Shoukry, A., Shalaby, S.M., Abdelazim, S., Abdelazim, M., Ramadan, A., Mabrouk, I., Fouad, M., 2012. Endothelial nitric oxide synthase gene polymorphisms and the risk of diabetic nephropathy in type 2 diabetes mellitus. Genet. Test. Mol. Biomark. 16 (6), 574-579. http://dx.doi.org/10.1089/gtmb.2011.0218.
42. Sun, H.Y., Yang, M.G., Liu, S.Q., Wang, C.J., Zhang, Q., Chen, M.W., 2004. Study on the correlation of the polymorphisms ofendothelial nitric oxide synthase gene with type 2 diabetesmellitus anddiabetic nephropathy. Chin. J. Prev. Contr. Chron. Non-commun. Dis. 12, 101-103.
43. Suwaidi, J.A., Hamasaki, S., Higano, S.T., Nishimura, R.A., Holmes Jr., D.R., Lerman, A., 2000. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation 101, 948-954.
44. Tanus-Santos, J.E., Desai, M., Flockhart, D.A., 2001. Effects of ethnicity on the distribution of clinically relevant endothelial nitric oxide variants. Pharmacogenetics 11, 719-725.
45. Tesauro, M., Thompson, W.C., Rogliani, P., et al., 2000. Intracellular processing of endothelial nitric oxide synthase isoforms associated with differences in severity of cardiopulmonary diseases: cleavage of proteins with aspartate vs. glutamate at position. Proc. Natl. Acad. Sci. U. S. A. 298 (97), 2832-2835.
46. Trinder, P., 1969. Determination of blood glucose using an oxidase-peroxidase method. Ann. Clin. Biochem 22 (2), 246.
47. Veelken, R., Hilgers, K.F., Hartner, A., 2000. Nitric oxide synthase isoforms and glomerular hyperfiltration in early diabetic nephropathy. J. Am. Soc. Nephrol. 11 (1), 71-79.
48. Villa, L.M., Salas, E., Darley-Usmar, V.M., et al., 1994. Peroxynitrite induces both vasodilatation and impaired vascular relaxation in the isolated perfused rat heart. Proc. Natl. Acad. Sci. U. S. A. 91, 12383-12387.
49. World Health Organization, 2006. Definition and DiagNOSis of Diabetes Mellitus and Intermediate Hyperglycemia. Available at www.who.int (Accessed February 20, 2011.).
50. Yoon, Y., Song, J., Hong, S.H., Kim, J.Q., 2000. Serum nitric oxide concentrations and nitric oxide synthase gene polymorphisms in coronary artery disease. Clin. Chem. 46 (10), 1626-1630.
51. Zanchi, A., Moczulski, D.K., Hanna, L.S., 2000. Risk of advanced diabetic nephropathy in type 1 diabetes is associated with endothelial nitric oxide synthase gene polymorphism. Kidney Int. 57, 405-413.
52. Zeng, Z., Li, L., Zhang, Z., et al., 2010. A meta-analysis of three polymorphisms in the endothelial nitric oxide synthase gene (NOS3) and their effect on the risk of DN. Hum. Genet. 127, 373-381.
53. Zintzaras, E., Papathanasiou, A., Stefanidis, I., 2009. Endothelial nitric oxide synthase gene polymorphisms and DN: a HuGE review and meta-analysis. Genet. Med. 11, 695-706.